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Introduction
High rates of psychopathology and, in particular, elevated 
rates of anxiety disorders are characteristic of some genetic 
syndromes associated with intellectual disability (ID; 
Dekker et al. 2002; Dykens 2000). High levels of anxiety 
frequently result in disruption to and restriction of activi-
ties, impaired quality of life and the need for psychological 
services (Davies et al. 1998; Plissart et al. 1994) Associa-
tions between these genetic syndromes and anxiety disor-
ders indicate a possible biological vulnerability, although 
the precise mechanisms are unknown (Jabbi et al. 2012). 
Thus, as well as being beneficial for diagnosis and inter-
vention, knowledge about the phenomenology of anxiety in 
genetic syndromes could help identify the possible neural 
and genetic mechanisms involved. One syndrome with a 
reportedly high prevalence1 of anxiety disorders is Williams 
syndrome (WS), which affects approximately one in 7500 
people (Stromme et al. 2002).
WS is caused by a sporadic microdeletion of 26–28 genes 
on chromosome 7q11.23 (Ewart et al. 993; Jarvinen et al. 
2013) and is associated with characteristic physical, cogni-
tive, emotional, and behavioural traits (Morris 2010). The 
physical phenotype includes delayed development, distin-
guishing facial features, cardiovascular disease, hypercalcae-
mia, short stature, and supravalvular aortic stenosis (Morris 
and Mervis 2000). The majority of individuals have mild to 
moderate ID, with IQs typically ranging from 40 to 90 (Bell-
ugi et al. 2000). The cognitive profile is uneven, with notable 
impairments in visuospatial processing skills but preserved 
expressive language and facial processing skills (Udwin and 
1 The term prevalence is used to describe the “number of cases of… 
[a] conditio , present at a particular time, in relation to the size of the 
population from which it is drawn” (Timmreck 2002, p. 151).
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Methodology
Search Strategy and Selection Criteria
The review was designed in accordance with PRISMA 
guidelines (Moher et al. 2009). Fiv  d tabases were selected 
for the systematic literature search; CINAHL (all years), 
Psychinfo (1967-April week 3 2015), Medline (1946-April 
week 3 2015), Embase (1974–2015 May 06), and Web of 
Science (all years). Appropriate search terms associated with 
WS were identified using medical subject headings (MeSH) 
definitions and genetics home reference terms. The terms, 
‘william’ and ‘beuren’ were also included to widen search 
results. Search terms related to anxiety were derived from 
the Diagnostic and Statistical Manual of Mental Disorders, 
Fifth Edition (DSM-5) categories of anxiety (American Psy-
chiatric Association [APA] 2013) and a literature review of 
anxiety in adults with ID (Hermans et al. 2011). The search 
was conducted using the search terms outlined in Table 1.
Study Selection
The multiple searches generated a total of 9201 refer-
ences. The initial search phase utilised predefined inclusion 
and exclusion criteria to screen the titles and abstracts of 
generated results (see Table 2). In cases where eligibility 
was unclear, a second reviewer screened the information 
and agreement regarding inclusion was reached. The term 
‘William’ generated numerous references that were not 
relevant to the syndrome under review, such as author’s 
names, models, and paradigms. Additionally, many studies 
did not explicitly reference anxiety and these studies were 
excluded. After the removal of duplicates, 80 relevant arti-
cles were retained.
Following the initial screen, a second phase with more 
stringent inclusion criteria was implemented when read-
ing the full text articles (Table 3). Only articles focusing 
on the prevalence rates of anxiety disorders were included 
Yule 1991; Bellugi et al. 2000). WS is also associated with 
an unusual social phenotype, whereby individuals tend to 
have an extremely strong drive for social interaction (Jones 
et al. 2000). The emotional and behavioural difficulties asso-
ciated with WS include anxiety, hyperactivity, impulsivity, 
distractibility, and disruptive behaviour (Einfe d et al. 1997, 
2001; Gagliardi et al. 2011; Pap eliou et al. 2012; Udwin and 
Yule 1991).
Anxiety is one of the most dominant and persistent dif-
ficulties for individuals with WS, although there is consider-
able variability in reported prevalence estimates, with figures 
for any anxiety disorders ra ging from 16.5 to 82.2 % (Stin-
ton et al. 2010; Woodruff-Borden et al. 2010). This variabil-
ity is likely the result of methodological differences between 
studies, in terms of the measures, diagnostic criteria, and 
samples (Dodd and Porter 2009; Green et al. 2012).
Despite discrepancies in estimates, the exte t to which 
anxiety is elevated in WS relat ve to the general popul tion 
is evident, with systematic reviews sugge ting that global 
rates in the general population are around 7–11 % (Baxter et 
al. 2013; Somers et al. 2006). Moreover, altho gh anxie y 
is a common feature in various genetic syndromes associ-
ated with ID (Emerson 2003), prevalence rat s are typically 
higher in WS compared with a number of synd omes, 
including Prader–Willi syndrom , Down synd om , nd 
Fragile X syndrome (Pegoraro et al. 2014; Dykens et al. 
2005). WS is also associated with high r rates of anxiety 
disorders compared with individuals with ID of m xed aeti-
ology, with rates estimated at 3–22 % (R ardon et al. 2015). 
Thus, it seems that high levels of anxie y in WS may not be 
solely related to the presence of ID; instead these findings 
suggest a specific link between WS and a heightened vulner-
ability for the development of anxiety, which may be related 
to genes in the area of the deletion region (Dykens 2000). To 
our knowledge, there has been no systematic s udy of rates 
of anxiety disorders in WS compared with rates in o her 
individuals with ID or in the general popula ion. Therefore, 
we conducted a meta-analysis of the literatu e to estimat  
the quality-weighted pooled prevalence rates of anxiety dis-
orders in WS and to compare the risk indices in WS with 
those for ID and the general population.
The aims of this review are to:
1. Amalgamate data from the existing literature and calcu-
late the pooled prevalence estimates of anxiety disorders 
in WS and ID, taking into account the methodological 
quality of the studies involved.
2. Identify and evaluate the methods most frequently used 
for measuring anxiety prevalence in WS.
3. Compare pooled prevalence estimates in individu-
als with WS with estimates for individuals with ID of 
heterogeneous aetiology, and to compare each of these 
with general population estimates.
Table 1 S arch terms used in electronic databases
Search terms
Group Abeuren syndrome* OR elfin facies syndrome* OR elfin 
facies with hypercalcemia* OR hypercalcemia-supra-
valvar aortic stenosis* OR infantile hypercalcemia* 
OR supravalvar aortic stenosis syndrome* OR WBS 
OR williams beuren syndrome* OR WMS OR WS OR 
williams syndrome* OR ch omosome 7q11.23 deletion 
syndrome* OR contiguous gene syndrome* OR williams 
contiguous gene syndrome* OR william* OR beuren*
Group Banx* OR phobi* OR fear* OR panic disorder* OR worr* 
OR panic attack*
Group A and group B were combined with the term ‘AND’
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were calculated using the statistical package MetaXL 2.0 
(Barendregt and Doi 2011). This was used to generate both 
random-effects models and quality-effects models of anxi-
ety disorder prevalence. The random-effects model, which 
accounts for variation between studies and estimates the 
mean of the distribution, was chosen over a fixed-effect 
model, which assumes studies share a common effect size 
(Borenstein et al. 2010). The quality weightings assigned to 
each study were also taken into consideration by calculating 
the quality-effects model (see Online Resource C for model 
summaries).
To account for studies involving overlapping cohorts of 
participants, only the data from the most methodologically 
robust study were retained. In cases where quality ratings 
did not differ, the study with the largest number of partici-
pants was included in the analysis.
Data from studies of WS were compared with pooled 
prevalence rates of anxiety disorders in ID of heterogeneous 
aetiology of both known and unknown origin; these latter 
figures were generated based on data reported in a recent 
systematic review by Reardon et al. (2015). Although the 
Reardon review (2015) primarily focuses on anxiety preva-
lence in children and adolescents (aged 5–20), it was, nev-
ertheless, deemed the most appropriate comparison for the 
WS data, as 75% of the WS studies included had a mean age 
of below 20 years. Although further matching of the cohorts 
(for age, cognitive level etc.) would have been preferable, 
(for full list of included and excluded studie , e Online 
Resource A). Through this process, 15 studies were identi-
fied as adhering to inclusion criteria. An additional manual 
scan of the articles’ reference lists identified one additional 
paper, resulting in a total of 16 papers. T e complet search 
strategy is presented in Fig. 1.
Quality Ratings
Methodological quality of the studies was rated using an 
adapted version of the criterion developed by R chards et al.
(2015) (see Online Resource B for full details). Inter-rater 
reliability for the original version is good, (r(52) = 0.78, 
p < 0.001; Richards et al. 2015). S udies were rated on a 
scale from poor (score of ‘0’) to excellent (‘3’) on three 
core areas; sample identification, confirmation of syndrome 
diagnosis, and anxiety assessment us d. Th  quality weight-
ings were calculated by divid ng the total quality score by 
the maximum score of nine. A second rat r indepe d tly 
rated 37.5 % of the papers and inter-rater reliability was 
good (kappa = 0.68).
Statistical Analysis
Estimated prevalence rates for anxiety disorders were 
extracted from the studies and pooled preval nce stimates 
Table 2 Phase one: Inclusion and exclusion criteria for screening 
titles and abstracts in preliminary search
Inclusion criteriaExclusion criteria
Diagnosis of Williams syndrome
Direct focus on anxiety
Studies published in English
Articles in peer reviewed journals
Non-human studies/mouse 
models
Studies discussing the phenom-
enology of social functioning 
or emotional processing with-
out a direct focus on anxiety
Conference abstracts, confer-
ence papers, book chapters
Table 3 Phase two: inclusion and exclusion criteria used to assess full 
text articles
Inclusion criteria Exclusion criteria
Studies with a psychiatric assessment/usage 
of DSM/ICD criteria
Studies reporting anxiety disorder preva-
lence rates (including any anxiety disor-
der, specific phobias, generalised anxiety, 
separation anxiety, social anxiety, panic 
disorder, agoraphobia, obsessive–com-
pulsive disorder and post-traumatic stress 
disorder)
Biological tudies/
genetic studies/bio-
marker studies
Intervention stu es
Reviews
Checklists/rating scales
Studie  using measures 
looking at a range of 
behaviours without 
anxiety as a focal 
point
Case studies
Database search:
n = 9201
[CINAHL (119), Psychinfo 
(1633), Medline (333), 
Embase (5539), Web of 
Science (1577)]
Rating 
scales/checklists    
n=7
Reviews
n = 22
Titles and abstracts 
searched (Phase I exclusion)
n = 260
Removal of duplicates
n = 80
Full article read (Phase II 
exclusion)
Excluded 
n = 65
Genetic/biological
/biomarker
n = 13
Interventions 
n = 7
Broad behavioural 
measures
n = 15
Case studies
n = 1
Excluded 
n = 8941
Reference lists searched
n= +1
Included in systematic review
n =16
Excluded 
n = 180
Fig. 1 Search strategy
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male to female ratio of 32:34. The average age of the par-
ticipants was 16.5 years (SD 8.9, range 4–55). Seven studies 
reported on the IQ level of participants; the mean was 64.43, 
SD  = 6.34 (range 56.6–75.6).
Quality Ratings
All WS studies failed to obtain the highest quality rating 
score of nine, however two (studies 3, 11) scored eight. The 
majority of papers (15, 93.8 %) obtained a score of three for 
syndrome confirmation but no studies achieved this score 
for sample identification. This was due to studies recruit-
ing from single or multiple research sites, and not from a 
random or total population sample, as was required for the 
maximum score. However, given the rarity of the syndrome, 
this method of sampling is not a feasible option. Quality 
scores for anxiety assessments were variable, with only five 
(31.3 %) studies (1, 3, 6, 8, 11) attaining the highest rating. 
This was achieved through reaching consensus using mul-
tiple measures, including at least one diagnostic assessment. 
All of the included studies were rated as being of ‘adequate’ 
or ‘good’ quality.
Anxiety Measures Used
Four standardised psychiatric assessments were used in the 
reviewed WS papers; two versions of the Kiddie Schedule 
of Affective Disorders (KSADS; Kaufman et al. 1997),
the Anxiety Disorder Interview Schedule (ADIS; Silver-
man and Albano 1996), the Diagnostic Interview Schedule 
for Children–Parent Version (DICA–R; Reich et al. 1991) 
and the Psychiatric Assessment Schedule for Adults with 
Developmental Disabilities (PAS-ADD; Moss et al. 1996).
The KSADS and ADIS were the most frequently used psy-
chiatric assessments, each used in seven studies. The most 
commonly used version of the KSADS, the present and 
lifetime version, has good test–retest reliability (present 
diagnoses, kappa = 0.74; lifetime diagnoses, kappa = 0.60) 
and strong inter-rater agreement (mean agreement =98 %, 
range = 93–100 %; Kaufman et al. 1997). The ADIS also 
has strong psychometric properties; test–retest reliabil-
ity is excellent (ICC = 0.81–0.96) and the reliability of 
anxiety disorder diagnoses range from good to excellent 
(kappa = 0.65–0.88; Silverman et al. 2001). Of the remain-
ing measures, the PAS-ADD, the only ID specific measure, 
is less robust, with particularly the anxiety disorder section 
being rated as having low validity (Moss et al. 1997). The 
DICA-R is based on an earlier version of the DSM and has 
been shown to have poor test–retest reliability for some 
anxiety disorders (kappa = 0.38–0.46; Boyle et al. 1993) 
and poor concordance with clinician judgements for specific 
phobias, post-traumatic stress disorder and obsessive–com-
pulsive disorder (Ezpeleta et al. 1997).
without access to the raw data this option was unavailable. 
The seven papers in the sys ematic ID review by Reardon 
et al. (2015) used criteria from either he Internationa Clas-
sification of Diseases (ICD-10; World Health Organisation 
[WHO] 1992) or the DSM-IV (APA 1994). The measures 
used included, the Development and Well-being Assessment 
(DAWBA; Goodman et al. 2000), the Diagnostic Interview 
Schedule for Children (DISC; Shaffer e  al. 2000), and c ini-
cian interviews. For the purp s the current review, the 
quality of the studies included in the Reardon et al. (2015) 
review were rated using the sa  methodology as for the WS 
papers. All of the ID papers were ra ed by two in pendent 
raters and inter-rater reliability was ood (kappa = 0.79).
To compare the risks of having an anxie y disorder i WS 
and ID, relative risk statistics were alculated using the qual-
ity-effects pooled prevalence estimates and 95 % confidence 
intervals. WS and ID prevalence est m tes re then com-
pared using odds ratio statistics with pooled popul ion esti-
mates of any anxiety disorder from two reviews, a child and 
adolescent focused meta-analysis (Polanczyk et al. 2015), to 
match the WS and ID studies, and a systematic review and
meta-regression inclusive of all age groups to reflect the gen-
eral population (Baxter et al. 2013). Both eviews (Baxter 
et al. 2013; Polanczyk et al. 2015) u ilised diagnostic pro-
cedures derived from the DSM or ICD (APA 1980, 1987, 
1994; WHO 1978, 1992), and included communi y s mples 
only. As there were no suitable reviews or pooled pr vale ce 
estimates for the individual cat gori s of anxiety disorders, 
a nation-wide UK survey of approxima ely 8000 5–16 year 
olds (Green et al. 2005) was chosen to co pare rates, using 
odds ratios with 95 % confidence intervals.
Results
Study Characteristics
Sixteen WS papers met the criteria for inclus on; eight of 
the studies were based in the US, f ur in Aust lia, two in 
Israel, one in the UK, and one in Brazil (Table 4). Publi-
cation dates of the papers identified ranged from 2003 to 
2014. Five American studies (numbered 9, 10, 11, 12, 15 
in Table 4) carried out assessments using the same cohort 
of participants, as did an additional four Australi n studies 
(2–5). Seven (43.75 %) studies utilised s mpl s of childr n
under the age of 18, seven (43.75 %) used broad age ranges 
including both children and adults, and the remaining two 
papers (studies 1, 14) focused on adult samples only.
A total of 1055 participants was included in the WS
meta-analysis; however, after accounting for individuals 
included in the overlapping c h rts, numbers reduce to 391 
participants. The mean sample size of all the included stud-
ies was n = 66 (SD 65.3; range 10–214), with an average 
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27.05, 95% CI 8.44–86.74; p <0.05), as well as in ID (OR 
4.00, 95% CI 1.14–13.98; p < 0.05), compared with popu-
lation estimates, although the odds were much higher for 
individuals with WS. Moreover, the odds of having a spe-
cific phobia (OR 79.28, 95 % CI 8.47–742.13; p < 0.05) or 
GAD (OR 13.78, 95 % CI 1.39–136.75; p < 0.05) were sig-
nificantly more likely in WS compared with the UK child 
population, although no differences were found for ID (see 
Online Resource F for further details).
Discussion
This is the first meta-analytical review to generate direct 
comparisons between rates of anxiety disorders in indi-
viduals with a specific genetic syndrome (WS) and those 
with heterogeneous ID, and population estimates. Random-
effects and quality-effects models were generated for WS 
and ID using the available WS literature and a pre-existing 
ID systematic review respectively, and statistical analysis 
of risk was used to compare estimates. The rate of anxiety 
disorder in individuals with WS was calculated at approxi-
mately 48 %, a significantly higher figure than the 12 % esti-
mated in the child ID population, and the variable yet lower 
estimates reported in the general population (Baxter et al. 
2013; Somers et al. 2006). Unexpectedly, the likelihood 
of developing an anxiety disorder in ID did not seem to be 
elevated compared to the general population, contrary to 
previous findings (Deb et al. 2001). However, as this review 
indicates, results are heavily dependent on the choice of 
comparison estimates. For example, there were discrepan-
cies between the odds calculated with the two global preva-
lence review papers (Baxter et al. 2013; Pol nczyk et al. 
2015) compared with the UK national survey (Green et al. 
2005). The reported rates of anxiety disorders in the study 
by Green et al. (2005) are low and thus may have inflated 
the differences in risk between the child population and ID 
group. These relatively low figures may be due to the fact 
that the Green et al. (2005) study relied entirely on paren-
tal reports of diagnosed disorders, which could potentially 
exclude a high proportion of individuals with undiagnosed 
anxiety. The significant variability in reported general popu-
lation estimates is also a limitation of much anxiety research, 
and is often attributed to the representativeness and frame of 
the sample and the choice of diagnostic instrument (Polanc-
zyk et al. 2015). As a result, comparative analyses in this 
context should be interpreted cautiously. Further investi-
gation is essential to decipher the relationship between ID 
and anxiety, as it remains unclear whether or not the pres-
ence of ID increases the likelihood of developing an anxiety 
disorder.
In contrast, it is evident that there is a strong relation-
ship between WS and the presence of anxiety disorders, and 
The measures provide both informant and self-report ele-
ments, and there was variation in the versions used between 
studies. Eleven of the studies obtained data by interviewing 
primary caregivers only; the remaining five (studies 1, 7, 8, 
14, 16), used a combination of both informant and respon-
dent interviews.
Prevalence Estimates and Profiles of Anxiety Disorders
The majority of papers (14, 87.5 %) us d anxiety assess-
ments that adhered to DSM-IV criteria (APA 1994). As a 
result, this review categorised dis rders according to this 
classification, rather than the more recent version (DSM-5; 
APA 2013). The random-effects and quality-effects pooled
prevalence estimates of anxiety disorders are eported i  
Table 5 (for all forest plots see Onlin  Resource D and E).
The data indicate that 48 % (95 % CI 26.0–70.0) of individ-
uals included in the review experie ced t least one anxi-
ety disorder. The most prev lent d sorder di gnosed was 
specific phobias (identified in nine studies; quality-effects 
39 %), and there were commonalitie  across studies regard-
ing the main phobias reported (Table 6). Among the top 
three phobias reported in each study, e most frequent pho-
bia was noise (n = 6); followed by, blood, injury or injection 
(n = 4); thunderstorms/lightning (n = 3); an mals (n = 3); and 
the category ‘other’ (n = 3). Generalised anxiety disorder 
(GAD) was also relatively common, with estim ted rates of 
10 % (95 % CI 4.0–19.0). The remaining anxi ty diso ders 
were less common, with the lowest estimate f r social anxi-
ety disorder (quality-effects 1%).
Generated prevalence estimates for anxiety di orders in 
WS were compared with ID population rat s using relative 
risk analyses. The results indicat  that individu ls with WS 
were significantly more likely to have an anxiety disorder 
[risk ratio (RR) 4.00 (95 % CI 2.27–7.06); p < 0.0001], and 
in particular, to have a specific phobia [RR 5.57 (95 % CI 
2.62–11.86); p < 0.0001] or GAD [RR 10.00 (95 % CI 1.30–
76.67); p< 0.05], than individuals with hetero eneous ID
(for full table of results, see Online Resource F).
Odds ratio statistics were used t  compare rate  of anxi-
ety disorders in WS and ID with gen r l populati n rates.
The odds of an anxiety disorder was significantly more 
likely in WS compared with child a d adolescent popul tion 
rates [Odds ratio (OR) 13.28, 95 % CI 5.47–32.22; p < 0.0 ] 
and all ages general population rat s [OR 11.72, 95 % CI 
5.01–27.41; p < 0.05]. There were no significant differences 
in the risk of having anxiety in the ID populat on compared 
to child/adolescent and general population rates.
Odds ratios statistics with 95 % confidence intervals were 
generated to compare WS and ID quality-effect  prevalence 
estimates of individual anx ety disorders with UK national 
child population estimates. Using he e estimates, having an 
anxiety disorder was significantly more likely in WS (OR 
1 3
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2015). This gene is hemizygously deleted in WS and is sug-
gested to account for the hyper-sociability and lower rates of 
social anxiety that are characteristic of WS (Schubert 2009; 
Sakurai et al. 2011). Additional research to investigate this 
association further is essential, as is exploration of the genetic 
influences of other anxiety disorders in WS, particularly spe-
cific phobias and GAD. This will enhance understanding of 
the roles and contributions of genetic and neural mechanisms 
in the development of anxiety disorders in WS, as well as in 
the general population.
Although many of the studies included in our review 
utilised similar psychometrically robust measures that cor-
respond to the same classification system (i.e. DSM-IV), 
comparability of prevalence rates between the papers should 
be interpreted carefully. Whilst the DSM tends to increase the 
number of diagnostic categories included in each revision, the 
ICD has remained more stable over recent editions (Cooper et 
al. 2003; Tyrer 2014). This may account for the lower anxiety 
prevalence rates reported by Stinton et al. (2010), an may 
have contributed to a lower pooled prevalence of anxiety for 
the ID studies. The choice of classification system has been 
shown to produce differing estimates (Slade and Andrews 
2001), demonstrating the importance of considering the 
measures and classifications used when interpreting results. 
Future studies introducing DSM-5 categorisation should also 
bear the likely discrepancies with previous criteria in mind.
Study Limitations
Out of the included studies, 37.5 % recruited participants 
from clinical settings. This may have inflated the prevalence 
estimates reported. In addition, the review was unable to 
match participants in the ID vs. WS comparative analyses, 
and so it is difficult to evaluate whether group differences 
may account for the differing anxiety rates reported. Einfeld 
and Tonge (1996) found a positive correlation between IQ 
and anxiety in individuals with ID, and since WS is mostly 
associated with a milder degree of ID (Bellugi et al. 2000), 
higher anxiety rates may be related to higher IQ levels. 
Additionally, WS is associated with an increased verbal abil-
ity, relative to other genetic syndromes and other forms of 
ID (Bellugi et al. 1990; Brock2007; Pegoraro et al. 2014). 
Thus, individuals with WS may be more able than others 
to express their internalising thoughts and feelings, which 
may lead to increased diagnosis (Ng et al. 2014). Neverthe-
less, the findings are consistent with other comparative stud-
ies indicating that anxiety disorders in WS are significantly 
more common than in heterogeneous ID groups.
The large confidence intervals generated in the analysis 
also reflect the current lack of methodologically robust stud-
ies in this area, which limits the ability to generate more 
precise prevalence estimates. The development of more 
stringent quality criteria is needed to enhance the reliability 
this association is mainly attributable to two categories of 
anxiety disorder: specific phobias and GAD. Specific pho-
bias were the most prevalent anxiety disorder reported in the 
WS samples (estimated at 39 %). Al hough these rates were
slightly elevated in the ID group (7 %) compared with UK 
child population estimates (0.8 %), they wer  m ch lower 
than risk estimates in WS. The c ntent of the phobias also 
appeared to be distinctive in WS, with reported phob as often 
relating to noise stimuli a d blood, injury and i jec ions, 
whereas the most commonly reported phobias in other stud-
ies of individuals with ID have included fears of ghosts and 
animals (Dykens 2003; Green et al. 2012). Certain phobias 
experienced by people with WS may be rela ed to some of 
the phenotypic characteristics of the dis rder, for exampl , a 
heightened sensitivity to aud tory stimuli (hyperacus s) and 
frequent hospitalisations/health problems may lead to f ars 
of loud noises and of blood/injury (Dykens2003). However, 
it is possible that reported rates of specific phobias are mis-
leading, particularly in relation to the prevalence of noise 
phobias. For those with hyperacusis (which is estimated 
to affect approximately 95 % of the WS population; Klein 
et al. 1990), loud noises are very aversive and can cause 
pain. Since irrationality is a core feature of the definition of 
a phobia (APA 2013), fear of noise may not be an irrational
response, and if such fears are incorrectly classified as pho-
bias, this could result in an overestimation in specific phobia 
prevalence rates. This issue is widely debated, and although 
it seems unlikely that noise phobias can fully account for the 
high rates of reported phobias, future research should con-
sider comparing the prevalence of phobias in WS with and 
without the inclusion of noise. Hyperacusis is also reported 
to decrease with age (Gothelf et al. 2006), therefore investi-
gating whether noise phobias are present t imilar rates in 
the adult WS population may shed fur h r light on wh ther 
this constitutes a true phobia in WS.
The high rate of GAD among WS participants w s also 
notable. Rates of GAD in ID samples were low (1 %) but the
risk of GAD increased ten-fold for ndividuals w th WS. Th  
high rates of phobias and GAD suggest that specific types of 
anxiety problems may be strongly associated with the genetic 
aetiology of WS, rather than with the presence of ID p r se. 
Preliminary evidence for this vulnerability stems from stud-
ies examining neurological and structural bra n differences in
WS. Structural deficits in white matter pathways have been 
implicated in the heightened amygdala activation obs ved for 
threatening stimuli in individual  with WS (Av ry e  al. 2011; 
Meyer-Lindenberg et al. 2005; Munoz et al. 2010; Thornton-
Wells et al. 2011). Such abnormalities may result in i creased 
prevalence of anxiety in WS, although furthe  rese rch to 
investigate the underlying mechanisms is warr nted. In terms 
of specific anxiety disorders, the GFT21 gene has been linked 
with dorsolateral prefrontal ortex activation and anxiety 
proneness in typically developing individuals (Jabb  et al. 
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anxiety and the effectiveness of interventions targeted 
towards specific phobias and GAD would seem to be par-
ticularly beneficial.
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